Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Metrics to compare | SERA | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipSERAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.2x | −3.3x | −0.6x | |
PEG Ratio | −0.17 | 0.02 | 0.00 | |
Price/Book | 1.7x | 1.7x | 2.6x | |
Price / LTM Sales | 1,458.5x | 121.4x | 3.2x | |
Upside (Analyst Target) | 39.3% | 14.5% | 41.8% | |
Fair Value Upside | Unlock | −4.8% | 5.1% | Unlock |